Galapagos and NCI sign US$5m deal

Will establish small molecule repository for new oncology therapeutics

The South San Francisco-based Compound Focus subsidiary of Galapagos’ BioFocus service division will provide compound management services to the US National Cancer Institute (NCI) in a three-year deal worth up to US$5m, with two, one-year extension options.

Under the agreement, Compound Focus will establish a Small Molecule Repository for the NCI Chemical Biology Consortium (CBC). This will form part of the CBC's drug discovery and development platform for new oncology therapeutics being researched by a consortium of academic institutions.

‘Compound Focus has done very well to expand its long-standing relationship with the NIH into this new project with the NCI,’ said Onno van de Stolpe, ceo of Galapagos.

‘Our compound management facility has met or exceeded its revenue objectives since we acquired it in 2006, making it a solid contributor to our service division's revenue stream.’

Companies